  |
|
|
 |
VIOXX® About VIOXX® - VIOXX® Recall On September 30, 2004 the anti-arthritis drug VIOXX® was withdrawn from the market by its manufacturer Merck & Co. In announcing its decision to pull VIOXX® from the market, Merck disclosed that data from its APPROVe study (Adenomatous Polyp Prevention on VIOXX®) demonstrated an increased risk of cardiovascular events such as heart attack and stroke for patients using VIOXX® for 18 months or longer. According to Merck, the APPROVe study did not demonstrate a similar risk for short-term users. The study was designed to assess the efficacy of VIOXX® in preventing the recurrence of colorectal polyps in a defined patient population. The withdrawal of VIOXX® from the market came shortly after the U.S. Food and Drug Administration approved the use of VIOXX® for children with juvenile rheumatoid arthritis on September 8, 2004. While Merck has consistently denied that there is any valid association between VIOXX® and an increased risk of cardiovascular events, there has been mounting evidence to support such an association. Earlier in 2004, a retrospective study of approximately 1.4 million patients of a nationwide health insurer indicated that those taking more than 25mg of VIOXX® daily had a three-fold risk of cardiovascular events than those not taking it. If you or a loved one has suffered a heart attack, heart arrhythmia, stroke or sudden cardiac death while taking VIOXX® and have questions about your legal rights, fill out our free case evaluation form. Choose the state where you live to locate a Vioxx lawyer near you. |
|
  |
||||||||||||||||||
